

**This announcement is important and requires your immediate attention. If you are in any doubt about the contents of this announcement, you should consult your bank manager, legal adviser, accountant or other independent financial adviser. China International Fund Management Co., Ltd. accepts full responsibility for the accuracy of the information contained in this announcement at the date of publication, and confirms, having made all reasonable enquiries, that to the best of its knowledge and belief there are no other facts the omission of which would make any statement in these documents misleading.**

**Announcement of China International Fund Management Co., Ltd. on Adjusting the Valuation of the Suspended Stock Guanhao Biotech (冠昊生物, 300238) Held by the Funds of the Company**

Based on the *Guiding Opinions on Further Standardizing the Valuation Operations of Securities Investment Funds* ([2008] Document No. 38) issued by the China Securities Regulatory Commission and with reference to the *Reference Methods for Valuing Suspended Stocks* issued by the Asset Management Association of China, as of January 25, 2016, the Company decides to adopt the index return method to value the suspended stock Guanhao Biotech (冠昊生物, 300238) held by Funds of the Company after consulting the custody bank.

The daily closing price will be used again for valuation of the aforementioned stock when stock trading resumes and its trading reflects the characteristics of active market transactions. No separate announcement will be given then.

This Notice is hereby given.

China International Fund Management Co., Ltd.

January 26, 2016

Should you have any questions regarding the contents of this announcement, please contact JPMorgan Funds (Asia) Limited:

- your bank or financial adviser;
- our Intermediary Hotline on (852) 2978 7788; or
- our Intermediary Clients' Hotline on (852) 2265 1000.